top of page

ASH 2025: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cell. Plus, the future of dual antigen and in vivo CAR-Ts. | 12/6/25

TOP VIDEO: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cel | 12/06/25

Quick Takes

Upcoming Events

November 3-5 - BIO-Europe 2025 | Vienna, Austria

November 6 - Oppenheimer Oncology Summit at University of Miami Sylvester | Miami, FL

November 7-9 - SITC Annual Meeting | National Harbour, MD

November 11-12 - Stifel Healthcare Conference | New York, NY

November 17-19 - Jefferies Global Healthcare Conference | London, UK

December 5-9 - ASH Annual Meeting | Orlando, FL

Science Spotlight
with Chloe Kirk

AI News with Ryan Flinn

12/11/25 - LabGenius Senior Scientist Rebecca Mighell showed us automated equipment that helps them develop T-cell engagers.

12/07/25 - Checking in (quickly) with Terns Pharma's CEO Amy Burroughs on the tern-701 data at ASH

12/07/25 - One of the first recipients of a gene therapy for sickle cell disease has a message for the industry at ASH.

Latest Videos

Create Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells." | 12/12/25

Company News:

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable.

12/12/2025

Klein Hersh at ASH

Klein Hersh:
Executive search experts from Klein Hersh discuss the job market dynamics in hematology and beyond

Sponsored

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization | 12/11/25

AI News:

Leaders of LabGenius discuss an ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi

12/11/2025

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today | 12/11/25

AI News:

Medra, which is building a robotics platform capable of doing fully automated lab work, announced a $52M series A today

12/11/2025

Biotech CEO Sisterhood: EpiBone creates bones and cartilage grown from stem cells - Co-Founder and CEO Nina Tandon describes the creative thinking she has used to accelerate its availability | 12/11/25

Biotech CEO Sisterhood:

Co-Founder and CEO Nina Tandon describes the creative thinking she has used to accelerate EpiBone's availability to patients

12/11//2025

Shows

Around Kendall Square

What's new at BiotechTV - from our founder

SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now | 01/16/25

09:50

SF Healthcare Week: Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets | 01/15/25

12:06

SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, BCMA, and lupus programs | 01/15/25

11:05

SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings | 01/13/25

09:45

SF Healthcare Week: The CEO of Arvians talks protein degradation, including about the industry's first phase 3 readout that is upcoming | 01/15/25

11:42

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more | 01/16/25

19:05

SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks | 01/14/24

12:13

SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development | 01/13/25

15:58

2025 SF Healthcare Week

ASCO25: Gilead Sciences Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more in the oncology pipeline | 05/31/25

15:21

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor | 06/01/25

09:08

Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry | 05/30/25

19:01

ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news | 05/30/25

09:58

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline | 05/31/25

08:29

ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation | 06/01/25

11:26

ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer | 06/01/25

11:00

ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors | 06/01/25

12:14

#ASCO25

ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual meeting | 12/7/24

14:22

Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune) | 12/7/24

13:56

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets | 12/8/24

13:29

Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

12:34

ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs | 12/7/24

09:41

ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company | 12/8/24

14:12

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025 | 12/8/24

11:37

Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma | 12/7/24

06:43

#ASH24

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page